Literature DB >> 14592307

Excessive daytime sleepiness in Parkinson's disease as assessed by Epworth Sleepiness Scale (ESS).

Suresh Kumar1, M Bhatia, M Behari.   

Abstract

OBJECTIVE: To assess daytime sleepiness in patients with Parkinson's disease (PD) using the Epworth Sleepiness Scale (ESS).
MATERIAL AND METHODS: One hundred and forty-nine patients with PD (126 men, 23 women) and 115 age matched controls recruited from relatives of medical staff or spouses and other family members accompanying patients to the Movement Disorder Clinic of the All India Institute of Medical Sciences in New Delhi were included in the study. An ESS score of > or =8 was considered abnormal. Data obtained were analyzed using Chi square test for categorical variables and Student's t-test for continuous variables.
RESULTS: The mean age of patients with PD was 58.37 (S.D.=10.45) years, and that of controls 56.50 (S.D.=11.45) years, with a mean duration of disease of 5.68 (S.D.=3.85) years. The mean ESS score was 4.9 (S.D.=3.63) and 2.17 (S.D.=2.54) in PD patients and controls, respectively (P<0.05). Thirty-two patients with PD (21%) had an ESS score of >8 whereas only 3% of controls scored > or =8 on the ESS (P<0.05). Higher ESS scores were associated with a higher Hoehn and Yahr (H&amp;Y) stage of disease and higher Unified Parkinson's Disease Rating Scale (UPDRS) (part I, III and total) scores (P<0.019, P<0.013 and P<0.011, respectively).
CONCLUSION: Excessive daytime sleepiness was more common in PD patients as compared to controls. Higher ESS scores correlated significantly with higher H&amp;Y stage and higher UPDRS (part I, III and total) scores.

Entities:  

Mesh:

Year:  2003        PMID: 14592307     DOI: 10.1016/s1389-9457(03)00105-9

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  30 in total

1.  Repeating administration of Epworth Sleepiness Scale is clinically useful.

Authors:  Denis Martinez; Tiago Cataldo Breitenbach; Magali Santos Lumertz; Denise Lerias Alcântara; Neusa Sicca da Rocha; Cristiane Maria Cassol; Maria do Carmo Sfreddo Lenz
Journal:  Sleep Breath       Date:  2010-11-10       Impact factor: 2.816

2.  Sleep in Parkinson's disease: a comparison of actigraphy and subjective measures.

Authors:  K Stavitsky; J L Saurman; P McNamara; A Cronin-Golomb
Journal:  Parkinsonism Relat Disord       Date:  2010-03-03       Impact factor: 4.891

3.  Abnormalities of vestibular-evoked myogenic potentials in idiopathic Parkinson's disease are associated with clinical evidence of brainstem involvement.

Authors:  Edoardo R de Natale; Francesca Ginatempo; Kai S Paulus; Giovanni M Pes; Andrea Manca; Eusebio Tolu; Virgilio Agnetti; Franca Deriu
Journal:  Neurol Sci       Date:  2015-01-08       Impact factor: 3.307

4.  Comparative levels of excessive daytime sleepiness in common medical disorders.

Authors:  Alice F Stroe; Thomas Roth; Catherine Jefferson; David W Hudgel; Timothy Roehrs; Kenneth Moss; Christopher L Drake
Journal:  Sleep Med       Date:  2010-10       Impact factor: 3.492

5.  Sleep quality in Parkinson disease: an examination of clinical variables.

Authors:  Karina Stavitsky; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2011-06       Impact factor: 1.600

6.  Sleepwalking in Parkinson's disease: a questionnaire-based survey.

Authors:  Michael Oberholzer; Rositsa Poryazova; Claudio L Bassetti
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

7.  Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial.

Authors:  A J Espay; A K Dwivedi; M Payne; L Gaines; J E Vaughan; B N Maddux; J T Slevin; M Gartner; A Sahay; F J Revilla; A P Duker; R Shukla
Journal:  Neurology       Date:  2011-04-05       Impact factor: 9.910

8.  Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.

Authors:  Tanya Simuni; Chelsea Caspell-Garcia; Christopher Coffey; Lama M Chahine; Shirley Lasch; Wolfgang H Oertel; Geert Mayer; Birgit Högl; Ron Postuma; Aleksandar Videnovic; Amy Willis Amara; Ken Marek
Journal:  Mov Disord       Date:  2015-06-11       Impact factor: 10.338

9.  Pimavanserin use in a movement disorders clinic: a single-center experience.

Authors:  Abhimanyu Mahajan; Bisena Bulica; Ayesha Ahmad; Patricia Kaminski; Peter LeWitt; Danette Taylor; Shana Krstevska; Neepa Patel
Journal:  Neurol Sci       Date:  2018-07-21       Impact factor: 3.307

10.  Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes.

Authors:  Sang Soo Cho; Kelly Aminian; Crystal Li; Anthony E Lang; Sylvain Houle; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2016-08-29       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.